Prolonged clinical benefit of everolimus therapy in the management of high-grade pancreatic neuroendocrine carcinoma

Case Reports in Oncology

Volumn 6, Issue 2, 2013, Pages 441-449

  Fonseca, Paula J ^a   Uriol, Esther ^a   Galván, José A ^b   Álvarez, Carlos ^a   Pérez, Quionia ^a   Villanueva, Noemi ^a   Berros, José P ^a   Izquierdo, Marta ^a   Viéitez, José M ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b UNIVERSITY OF OVIEDO   (Spain)

Author keywords

Everolimus; Neuroendocrine tumors; Octreotide long acting repeatable; Pancreatic

Indexed keywords

CAPECITABINE; CHROMOGRANIN A; CISPLATIN; DEXAMETHASONE; DOXORUBICIN; ERYTHROPOIETIN; ETOPOSIDE; EVEROLIMUS; FLUOROURACIL; IRON; KI 67 ANTIGEN; MORPHINE; OCTREOTIDE; OPIATE; PACLITAXEL; SCOPOLAMINE BUTYL BROMIDE; SOMATOSTATIN RECEPTOR; STREPTOZOCIN; SYNAPTOPHYSIN; TEMOZOLOMIDE;

ADULT; ANEMIA; ANOREXIA; ANTIGEN EXPRESSION; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER GROWTH; CANCER INFILTRATION; CANCER MORTALITY; CANCER PAIN; CANCER TISSUE; CASE REPORT; CAUSE OF DEATH; COMPUTER ASSISTED TOMOGRAPHY; DIABETIC DIET; DIARRHEA; DISEASE COURSE; DRUG MEGADOSE; EATING DISORDER; ECHOCARDIOGRAPHY; EPIGASTRIC PAIN; ESOPHAGITIS; FATIGUE; FEMALE; FEVER; GENERAL CONDITION DETERIORATION; HAND FOOT SYNDROME; HEPATOMEGALY; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; IRON THERAPY; JAUNDICE; LIVER BIOPSY; LIVER FAILURE; LIVER METASTASIS; LONG TERM EXPOSURE; MULTIPLE CYCLE TREATMENT; NAUSEA; PANCREATIC NEUROENDOCRINE TUMOR; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCINTIGRAPHY; SMALL INTESTINE OBSTRUCTION; STOMATITIS; TOXICITY; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR VOLUME; VOMITING;

EID: 84885638417     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000354754     Document Type: Article

References (15)

1. Yao JC, Eisner MP, Leary C, Dagohoy C, Phan A, Rashid A, Hassan M, Evans DB: Population-based study of islet cell carcinoma. Ann Surg Oncol 2007;14:3492-3500.
2. Oberg K, Akerstrom G, Rindi G, Jelic S: Neuroendocrine gastroenteropancreatic tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(suppl 5):v223-v227.
3. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evans DB: One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063-3072.
4. Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC: Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004;22:4762-4771.
5. Delaunoit T, Ducreux M, Boige V, Dromain C, Sabourin JC, Duvillard P, Schlumberger M, de Baere T, Rougier P, Ruffie P, Elias D, Lasser P, Baudin E: The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma: a judicious option? Eur J Cancer 2004;40:515-520.
6. Kulke MH, Bendell J, Kvols L, Picus J, Pommier R, Yao J: Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. J Hematol Oncol 2011;4:29.
7. Eriksson B, Annibale B, Bajetta E, Mitry E, Pavel M, Platania M, Salazar R, Plöckinger U; on behalf of Mallorca Consensus Conference participants and the European Neuroendocrine Tumor Society: ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: chemotherapy in patients with neuroendocrine tumors. Neuroendocrinology 2009;90:214-219.
8. Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, Wiseman GA, Kvols LK; for the North American Neuroendocrine Tumor Society: The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas 2010;39:799-800.
9. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F: Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008;26:4311-4318.
10. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K; for the RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group: Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514-523.
11. Pavel M, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC; for the RADIANT-2 Study Group: Everolimus plus octreotide long-Acting repeatable for the treatment of advanced neuroendocrine tumors associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011;378:2005-2012.
12. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L: First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011;117:268-275.
13. Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, Mayer C, Aminossadati B, Pape UR, Bläker M, Harder J, Arnold C, Gress T, Arnold R; for the PROMID Study Group: Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656-4663.
14. Shida T, Kishimoto T, Furuya M, Nikaido T, Koda K, Takano S, Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Tanizawa T, Nakatani Y, Miyazaki M: Expression of an activated mammalian target of rapamycin (mTOR) in gastroenteropancreatic neuroendocrine tumors. Cancer Chemother Pharmacol 2010;65:889-893.
15. Catena L, Bajetta E, Milione M: Mammalian target of rapamycin expression in poorly differentiated endocrine carcinoma: clinical and therapeutic future challenges. Targeted Oncol 2011;6:65-68.